Dr. Sutcliffe has more than 35 years of experience in antibiotic research and development. She is the former Senior Vice President for Tetraphase Pharmaceuticals, Inc. where her responsibilities encompassed managing the discovery biology and preclinical development internally and with outside contractors. She was part of the executive team involved in strategy for clinical development, marketing assessments, budgeting, resource allocation, interactions with regulatory agencies, government contract writing, and management of awarded contracts. Tetraphase antibiotics eravacycline and TP-271 received support for their development from BARDA and NIAID respectively of $100 million.

Prior to joining Tetraphase, Joyce was Vice President of Research at NanoBio Corporation where she led antimicrobial, antiviral and antifungal discovery activities. In addition, she was Chief Research Scientist for six years at Rib-X Pharmaceuticals and spent 20 years at Pfizer and Abbott where she played key roles in antibiotic discovery and development through Phase 2 activities. Antibiotics that entered phase 2 and beyond that she helped develop are eravacycline, radezolid, delafloxacin, nanoemulsions as antifungals and for adjuvant vaccines, and azithromycin. She is currently part of the Scientific Advisory Board for Innovative Platforms for Antimicrobial Therapy and Vaccine Development awarded to Harvard University by NIAID, TB Alliance, the Small World Initiative and has served as a scientific advisor to PEW Charitable Trusts.

Dr. Sutcliffe received her Ph.D. in Microbiology from the University of Florida, Gainesville, followed by a postdoctoral position at the University of Massachusetts Medical School and a staff fellowship at the National Institutes of Health.